Common Equity: The sum of all common equity items.
Tarsus Pharmaceuticals, Inc. (TARS) had Common Equity of $343.43M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$151.67M |
|
$-8.37M |
|
$10.93M |
|
$140.74M |
|
$159.64M |
|
$-7.98M |
|
$1.66M |
|
$-6.31M |
|
$-6.31M |
|
$-8.37M |
|
$-8.37M |
|
$-8.37M |
|
$-8.37M |
|
$-7.98M |
|
$-8.30M |
|
41.78M |
|
41.78M |
|
$-0.17 |
|
$-0.17 |
|
| Balance Sheet Financials | |
$522.78M |
|
$11.66M |
|
$39.38M |
|
$562.16M |
|
$135.69M |
|
$72.44M |
|
$83.04M |
|
$218.73M |
|
|
Common Equity |
$343.43M |
$336.06M |
|
$343.43M |
|
42.55M |
|
| Cash Flow Statement Financials | |
$-12.45M |
|
$-42.12M |
|
$143.39M |
|
$97.38M |
|
$186.20M |
|
$88.82M |
|
$41.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.85 |
|
-- |
|
-- |
|
0.17 |
|
0.21 |
|
92.80% |
|
-5.26% |
|
-5.26% |
|
-- |
|
-4.16% |
|
-5.52% |
|
$-22.31M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
2.50 |
|
1.74 |
|
51.69 |
|
-2.44% |
|
-2.49% |
|
-1.49% |
|
-2.01% |
|
$8.07 |
|
$-0.53 |
|
$-0.30 |
|